Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17108208 | 0.89 | HRH4 (0.35) | MAOACYP19A1HRH3HRH4PIM1 | |
| Hydrochloric Acid SCHEMBL17048491 | 0.88 | HRH4 (0.34) | MAOACYP19A1HRH3HRH4 | |
| SCHEMBL2877085 | 0.82 | CYP2B6 (0.44) | CYP19A1HRH4CYP2B6 | |
| SCHEMBL27989235 | 0.82 | CYP2B6 (0.40) | CYP19A1HRH4CYP2B6 | |
| SCHEMBL8542846 | 0.82 | PIM1 (0.38) | MAOABRD4CYP19A1HRH3PIM1 | |
| SCHEMBL18325457 | 0.81 | CYP2B6 (0.47) | CYP19A1HRH3HRH4CYP2B6 | |
| SCHEMBL18325220 | 0.81 | CYP2B6 (0.47) | CYP19A1HRH3HRH4CYP2B6 | |
| SCHEMBL30165007 | 0.81 | CYP19A1 (0.36) | MAOACYP19A1 | |
| SCHEMBL21359356 | 0.80 | HRH3 (0.38) | HRH3HRH4BRAFMAPK3MAPK1 | |
| SCHEMBL15958943 | 0.76 | CYP2B6 (0.36) | CYP19A1CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0160620-B1 | METAL DEACTIVATORS | CIBA-GEIGY AG (CH) | 1989-09-13 | — | — | EP | claimed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
| EP-0160620-B1 | METAL DEACTIVATORS | CIBA-GEIGY AG (CH) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | MAOA 344/4885BRD4 721/4885CYP19A1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.